Results 181 to 190 of about 45,078 (268)

Oral cholera vaccine coverage in Goma, Democratic Republic of the Congo, 2022, following 2019-2020 targeted preventative mass campaigns. [PDF]

Vaccine X
Briskin E, Bateyi Mustafa SH, Mahamba R, Kabunga D, Kubuya J, Porten K, Epicentre-MSF DRC cholera working group, Akilimali L, Okitayemba Welo P, Broban A.   +9 more
europepmc   +1 more source

Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia. [PDF]

PLoS One, 2021
Luchen CC, Mwaba J, Ng'ombe H, Alabi PIO, Simuyandi M, Chilyabanyama ON, Hatyoka LM, Mubanga C, Bosomprah S, Chilengi R, Chisenga CC.   +10 more
europepmc   +1 more source

Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit [PDF]

, 2011
Le Guo, Xiaokang Li, Feng Tang, Yunmian He, Yingying Xing, Xuepeng Deng, Tao Xi   +6 more
openalex   +1 more source

Challenges with achieving and maintaining oral cholera vaccine coverage: insights from serial cross-sectional representative surveys in a cholera-endemic community in the Democratic Republic of the Congo. [PDF]

BMJ Public Health
Koyuncu A, Bugeme PM, Dent J, Hutchins C, Xu H, Gallandat K, Cumming O, Matundanya J, Cikomola A, Rukakiza D, Nkombo M, Mufitini JS, Bashige Rumedeka B, Akilimali L, Lee EC, Welo PO, Knee J, Azman AS, Malembaka EB.   +18 more
europepmc   +1 more source

Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial. [PDF]

Lancet Infect Dis, 2021
Ali M, Qadri F, Kim DR, Islam MT, Im J, Ahmmed F, Khan AI, Zaman K, Marks F, Kim JH, Clemens JD.   +10 more
europepmc   +1 more source

Insights into enterotoxigenic Escherichia coli diversity in Bangladesh utilizing genomic epidemiology [PDF]

, 2017
A Bankevich, A Mentzer von, A Sjoling, AC Vicente, AM Almeida de, AR Quinlan, AR Wattam, C Lindenthal, CA Jacobi, D Hernandez, DA Rasko, DA Rasko, DG Evans, DJ Ingle, EW Myers, F Canto Del, F Canto Del, F Qadri, GB Lindblom, GP Munson, H Steinsland, HL DuPont, HL DuPont, I Bolin, I Letunic, JM Fleckenstein, JM Fleckenstein, JM Fleckenstein, JS Farris, JW Sahl, JW Sahl, JW Sahl, JW Sahl, JW Sahl, K Hayashi, K Roy, K Roy, K Roy, K Schliep, KL Kotloff, LC Crossman, M So, M So, MA Lasaro, MN Price, MS Donnenberg, P Kumar, Q Luo, R Lozano, RA Finkelstein, RA Nada, RB Sack, RC Edgar, RI Walker, S Schubert, SF Altschul, SK Patel, SM Turner, T Seemann, T Wirth, TH Hazen, W Gaastra, WHO   +62 more
core   +2 more sources

Knowledge and perception of a clinical trial among the participants: An experience from oral cholera vaccine study in Koshi Province, Nepal. [PDF]

Hum Vaccin Immunother
Chaudhary S, Uranw S, Rai B, Keshary Bhatta N, Shah GS, Poudel P, Khanal B, Shah Kalawar RP, Rai N, Shrestha J, Shrestha M, Parajuli S, Gupta BP, Vemula S, Rok Song K, Lynch J, Saluja T.   +16 more
europepmc   +1 more source

CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe. [PDF]

Sci Rep, 2021
Duffin RP, Delbuono M, Nishioka K, Shabram P, Patel AA.   +4 more
europepmc   +1 more source

Cholera vaccines for the rich, cholera for the poor: While the global cholera vaccine stockpile runs dry, a booming market for high-income countries exemplifies the chasm between commercial interests and global health needs. [PDF]

PLOS Glob Public Health
Houston AR, Houston S.
europepmc   +1 more source

Association of post-diagnostic use of cholera vaccine with survival outcome in breast cancer patients. [PDF]

Br J Cancer, 2021
Zheng G, Sundquist J, Sundquist K, Ji J.
europepmc   +1 more source